T1	Participants 33 151	antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial
T2	Participants 325 554	MONotherapy AntiRetroviral Kaletra (MONARK) is the first randomized trial comparing lopinavir/ritonavir monotherapy to triple combination therapy with zidovudine/lamivudine and lopinavir/ritonavir in antiretroviral-naïve patients
T3	Participants 575 709	136 antiretroviral-naïve patients, with a CD4 cell count above 100 cells/microL and a plasma HIV RNA below 100,000 HIV-1 RNA copies/mL
T4	Participants 864 935	patients in the lopinavir/ritonavir monotherapy arm followed to week 96
T5	Participants 1461 1537	o week 96, a total of 28 patients (34%) had discontinued the study treatment
T6	Participants 1566 1606	treatment was changed for seven patients
